RLMD
NASDAQ HealthcareRelmada Therapeutics, Inc. - Common Stock
Biotechnology
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
๐ Market Data
| Price | $7.64 |
|---|---|
| Volume | 941,796 |
| Market Cap | 801.36M |
| RSI (14-Day) | 55.7 |
| 200-Day MA | $3.58 |
| 50-Day MA | $6.33 |
| 52-Week High | $7.94 |
| 52-Week Low | $0.32 |
| Forward P/E | -18.63 |
| Price / Book | 6.47 |
๐ฏ Investment Strategy Scores
RLMD scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (50/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ช Falling Knife (5/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find RLMD in your text
Paste any article, transcript, or post โ the tool will extract RLMD and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.